Humanigen Inc., a drug developer that raised money to treat severe Covid patients, filed for bankruptcy after its leading product was rejected by regulators.
- The company, based in Burlingame, California, listed assets of $521,000 and debt of more than $44 million in its Chapter 11 petition; the company had previously filed bankruptcy in 2015
- Humanigen will try to sell itself while under court protection, it said in court papers filed in Wilmington, Delaware
- The company failed to win regulatory approval for anti-inflammatory immunology drug called lenzilumab, which was being tested as a treatment for certain patients hospitalized with Covid-19
- In ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.